stockrow
Friday 6 November 2026
Export HLN’s income statement to Excel — free account
Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
9.13
0.10
−1.08%
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) Shares outstanding
Haleon PLC Sponsored ADR's shares outstanding at the end of fiscal 2025 was $4.5B, unchanged from fiscal 2024. Over the past ten years it has ranged from $4.5B (fiscal 2025) to $4.6B (fiscal 2023) — the current reading is the lowest in ten years. Haleon PLC Sponsored ADR ranks 1st of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $4.5B | (1.62%) |
| FY2024 | $4.6B | (0.95%) |
| FY2023 | $4.6B | 0.26% |
| FY2022 | $4.6B | (0.02%) |
| FY2021 | $4.6B | 0.00% |
| FY2020 | $4.6B | 0.00% |
| FY2019 | $4.6B | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Mar 2024 | $4.6B | (0.75%) |
| Jun 2023 | $4.6B | 0.05% |
| Mar 2023 | $4.6B | — |
Against its own ten years
Low $4.5B
High $4.6B
Ten-year median
$4.6B
Current reading's percentile
14
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| HLN Haleon PLC Sponsored ADR | $4.6B |
| TAK Takeda Pharmaceutical Co. compare | $3.2B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $1.2B |
| VTRS Viatris Inc. compare | $1.2B |
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| ZTS Zoetis Inc. compare | $417.7M |
| NBIX Neurocrine Biosciences, Inc. compare | $105.2M |
| UTHR United Therapeutics Corporation compare | $45.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement